Special Issue "Antibody Engineering for Cancer Immunotherapy".

Crescioli, Silvia; White, Ann L; Karagiannis, Sophia N

Crescioli, Silvia; White, Ann L; Karagiannis, Sophia N.

Afiliação

Crescioli S; St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, London SE1 9RT, UK.
White AL; UCB Celltech, Slough SL1 3WE, UK.
Karagiannis SN; St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, London SE1 9RT, UK.

Antibodies (Basel) ; 11(2)2022 Apr 15.

Article em En | MEDLINE | ID: mdl-35466282

ABSTRACT

ABSTRACT

Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Antibodies (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Antibodies (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido